Search the Newsreel

LeMaitre says Artegraft is now approved in 56 countries

LeMaitre (NASDAQ: LMAT) reported strong Q2 2026 financial results with net sales up 10% year-over-year to $70.4 million and diluted EPS up 23% to $0.74. A key growth driver was Artegraft, whose sales increased by 34%, now representing 21% of total sales and approved …

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Exploring a 14.61% Potential Upside in the Healthcare Sector

LeMaitre Vascular, Inc. (LMAT) is a significant player in the healthcare sector, specifically in medical instruments for vascular surgery, with a market capitalization of $2.37 billion. The company shows strong financial health with 11.20% revenue growth, a 16.55% return on equity, and a forward …

LeMaitre Vascular earnings on deck as margin gains test continues

LeMaitre Vascular is set to announce its second-quarter earnings, with investors closely watching its ability to maintain significant margin expansion and accelerate profit growth. Analysts anticipate earnings of $0.81 per share on revenue of $71.5 million, reflecting substantial year-over-year growth. The company's premium valuation …

LeMaitre Q2 2026 Financial Results

LeMaitre Vascular, Inc. reported strong Q2 2026 financial results with sales up 10% to $70.4 million and EPS up 23% to $0.74, driven by a 34% increase in Artegraft sales and operational efficiencies. The company announced a quarterly dividend of $0.25/share and provided optimistic …

LeMaitre: Q2 Earnings Snapshot

LeMaitre Vascular Inc. (LMAT) reported a second-quarter profit of $17.1 million, or 74 cents per share, on revenue of $70.4 million. The medical device maker anticipates revenue for the current quarter to be between $66.3 million and $68.3 million, with full-year earnings projected at …

LeMaitre Vascular, Inc. $LMAT Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC reduced its stake in LeMaitre Vascular, Inc. (LMAT) by 34.9% in the first quarter, selling 27,990 shares and retaining 52,252 shares valued at approximately $5.7 million. The medical instruments supplier reported strong Q1 earnings, beating estimates with $0.68 EPS …

LeMaitre (NASDAQ:LMAT) Misses Q2 CY2026 Revenue Estimates, Stock Drops 11.6%

LeMaitre (NASDAQ:LMAT) Misses Q2 CY2026 Revenue Estimates, Stock Drops 11.6% Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street's revenue expectations in Q2 CY2026, but sales rose 9.6% year on year to $70.38 million. Next quarter's revenue guidance of $67.3 million underwhelmed, coming in …

LeMaitre Vascular (NASDAQ:LMAT) Posts Earnings Results

LeMaitre Vascular (LMAT) Earnings Date and Reports 2026

LeMaitre (LMAT) Reports Earnings Tomorrow: What To Expect

LeMaitre (LMAT) Reports Earnings Tomorrow: What To Expect Medical device company LeMaitre Vascular (NASDAQ:LMAT) will be announcing earnings results this Tuesday after market close. Here's what you need to know. LeMaitre met analysts' revenue expectations last quarter, reporting revenues of $66.55 million, up 11.2% …

LeMaitre Vascular (LMAT) Holds A 15% Undervalued View, Is The Stock Fully Priced?

LeMaitre Vascular (LMAT) closed at $101.32 on July 29, 2026, and is considered 15% undervalued with a fair value of $118.75 based on analyst forecasts and a strong product pipeline. However, its P/E ratio of 37.1x screens as expensive against the market and industry, …

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Rating of "Moderate Buy" by Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received an average "Moderate Buy" rating from brokerages, with an average 12-month price target of $112.60. The company recently surpassed quarterly EPS expectations and saw an 11.1% revenue increase. Despite insider stock sales totaling approximately $5.9 million, institutional investors …

Precision Trading with Lemaitre Vascular Inc. (LMAT) Risk Zones

This article from Stock Traders Daily provides a detailed analysis of Lemaitre Vascular Inc. (LMAT) focusing on precision trading strategies and risk zones. It highlights near-term strong sentiment, mid-term neutrality, and long-term positive bias, along with specific entry, target, and stop-loss levels for different …

Sei Investments Co. Boosts Stock Holdings in LeMaitre Vascular, Inc. $LMAT

Sei Investments Co. increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 30.7% in the first quarter, now holding 136,674 shares valued at $14.92 million. Other

Pulmatrix Inc (PULM) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Pulmatrix Inc (PULM), ranking its financial status as robust with a score of 6.80 within the Biotechnology & Medical Research industry. Key financial dimensions like Quality of Earnings and Shareholder Returns are also rated. However, several financial …

Pulmatrix Inc (PULM) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Pulmatrix Inc (PULM), stating its current valuation score is 6.63, ranking 276 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.40, noting it is significantly below its …

Pulmatrix Inc (PULM) Income Statement

This article provides the quarterly and annual income statements for Pulmatrix Inc (PULM), detailing financial performance metrics such as total revenue, operating expenses, and net income. It also includes frequently asked questions about how to interpret these financial statements and key metrics for analyzing …

LeMaitre Vascular Inc (LMAT) Institutional Confidence

LeMaitre Vascular Inc (LMAT) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. This score reflects a quarter-over-quarter increase of 8.41% in institutional shareholding proportion, which currently stands at 102.98%. ETHSX is the largest institutional shareholder, …

LeMaitre Vascular Inc (LMAT) Financial Health: Profitability & Balance Sheet Analysis

LeMaitre Vascular Inc (LMAT) has a robust financial status with a current financial score of 9.04, ranking 11th in the Healthcare Equipment & Supplies industry. The company demonstrated high operating efficiency with a 11.16% year-over-year increase in quarterly revenue to $66.55M and a 42.39% …

LeMaitre Vascular (LMAT) insider Bridget Ross files to sell 4,322 shares

LeMaitre Vascular insider Bridget A. Ross has filed to sell 4,322 shares of common stock, valued at $449,241.48, through a Form 144. The sale is expected on July 29, 2026, and relates to a stock option exercise. Ross previously sold 5,044 shares for $560,366.40 …

LeMaitre Vascular, Inc. Revenue Breakdown – FWB:LHU

LeMaitre Vascular, Inc. (FWB:LHU) generated 212.52 million EUR last year, primarily from its Medical Devices and Human Tissue Cryopreservation segment. The United States was the company's largest regional contributor, accounting for 120.53 million EUR of the revenue. This data highlights the key revenue drivers …

LeMaitre Vascular (LMAT) to Announce Earnings on Tuesday

LeMaitre Vascular (LMAT) is set to release its Q2 2026 earnings on Tuesday, August 4th, with analysts forecasting EPS of $0.81 and revenue of $71.473 million. This follows a strong previous quarter where the company surpassed EPS estimates by $0.02 and saw an 11.1% …

PULM|Pulmatrix Inc|Price:1.670|Chg%:-0.060

This article provides a comprehensive stock analysis of Pulmatrix Inc (PULM) from TradingKey, highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It notes strong institutional ownership and a medium-term upward trend expectation for the …

First Trust group (NASDAQ: LMAT) reports 1.18M-share, 5.15% ownership position

First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation have collectively reported a beneficial ownership of 1,175,902 shares of LeMaitre Vascular, Inc. common stock, which represents 5.15% of the class. The group holds shared voting power over 1,170,364 shares and shared …

Pulmatrix Inc (PULM) Cash Flow

This article provides a detailed cash flow statement for Pulmatrix Inc (PULM), covering quarterly and annual data from FY2013Q1 to FY2026Q1. It breaks down operating, investing, and financing cash flows, along with changes in working capital and net income from continuing operations. The document …

LeMaitre Vascular Inc (LMAT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividend payouts and events for LeMaitre Vascular Inc (LMAT), detailing dividend amounts, record dates, payment dates, and ex-dividend dates up to May 2026. It also includes current stock information such as market capitalization, P/E ratio, and recent …

Pulmatrix Inc (PULM) Institutional Confidence

Pulmatrix Inc (PULM) has an institutional shareholding score of 3.00, placing it 191st out of 384 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 8.89% quarter-over-quarter, reaching 10.12%. James Simons is the largest institutional shareholder, holding 2.99% …

Pulmatrix Inc (PULM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pulmatrix Inc (PULM) stock information, focusing on its dividend history and stock split events. It indicates that the company has not distributed dividends in the past five years and lists multiple stock splits that occurred on February 25, …

Pulmatrix Inc (PULM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pulmatrix Inc (PULM), listing its major institutional holders and their respective proportionate holdings. Key institutional shareholders include Renaissance Technologies LLC, BlackRock Institutional Trust Company, N.A., and Geode Capital Management, L.L.C. The report also provides a historical overview …

Pulmatrix, Inc. Revenue Breakdown – NASDAQ:PULM

This article provides a brief overview of Pulmatrix, Inc. with its NASDAQ stock symbol PULM. It focuses on the company's financial data, including statements, statistics, dividends, earnings, and segment performance. The content is primarily a navigation hub rather than a detailed financial report.

PULM|Pulmatrix Inc|Price:1.650|

Pulmatrix Inc (PULM) is a biopharmaceutical company focused on developing inhaled therapeutic products for respiratory and CNS diseases using its iSPERSE technology. The company's stock shows healthy fundamentals and high growth potential, though its market activity is low. The stock is currently trading sideways, …

LMAT|LeMaitre Vascular Inc|Price:98.390|Chg%:+0.900

LeMaitre Vascular Inc. (LMAT) is a company that develops, manufactures, and markets devices and services for the treatment of peripheral vascular disease. The article provides an overview of the company, including its stock performance, market capitalization, P/E ratio, and executive team. It also lists …

First Trust Advisors LP Acquires 57,931 Shares of LeMaitre Vascular, Inc. $LMAT

First Trust Advisors LP increased its stake in LeMaitre Vascular (NASDAQ:LMAT) by 6.2% during the first quarter, now holding 998,071 shares valued at $108.96 million. Other institutional investors also adjusted their positions in the company, while insiders have sold shares totaling over $5.9 million …

Citizens reiterates LeMaitre Vascular stock rating on growth outlook

Citizens has reiterated a "Market Outperform" rating and $127.00 price target for LeMaitre Vascular (NASDAQ: LMAT) shares, citing the company's strong fiscal 2026 guidance, which includes 12% organic growth and 22% adjusted EPS growth. The company also recently raised its profit and margin guidance, …

Technical Reactions to LMAT Trends in Macro Strategies

This article provides a technical analysis of Lemaitre Vascular Inc. (NASDAQ: LMAT) based on AI models. It indicates a near-term neutral sentiment amidst mid and long-term strength, with resistance being tested. The analysis offers specific institutional trading strategies including position trading, momentum breakout, and …

Bessemer Group Inc. Boosts Position in LeMaitre Vascular, Inc. $LMAT

Bessemer Group Inc. significantly increased its stake in LeMaitre Vascular, Inc. by 292.3% during the first quarter, now owning 171,838 shares valued at $18.76 million. Other institutional investors also adjusted their positions, and 84.64% of the stock is held by hedge funds and institutions. …